Market screen highlights three U.S.-listed stocks grouped with Moderna’s past surge pattern

Shares of Moderna have often moved sharply when investors switch into higher-risk, high-expectations modes around biotech-style catalysts. In a recent market note carried by Yahoo Finance, the focus shifted from Moderna itself to what the article described as a repeatable trading setup that previously drove a very large single-day move in the company’s stock.

The post’s headline referred to a period when Moderna shares jumped roughly 177% on the day, and it attributed that surge to five conditions, suggesting a mix of price action and technical factors rather than a single fundamental event. The authors then ran a screen to identify other U.S.-listed stocks that matched that same “setup.”

According to the article description, the screen produced three additional American-listed stocks that fit the same five conditions. The post said that none of the three were biotech companies, a point that matters because it implies the pattern is not limited to the specific industry that Moderna represents.

The same market note framed the idea as a way to look for similar behavior across the broader market, even when the underlying businesses differ. In other words, the screening approach was less about shared drug pipelines or platform technology, and more about whether the stocks were exhibiting the same market mechanics the article said propelled Moderna’s historic day.

Moderna, ticker MRNA, remains the reference point for the screen because of the magnitude of the move cited in the note. Moderna is known primarily for developing messenger RNA (mRNA) medicines, a platform that allows instructions in the form of RNA to be delivered to the body so cells can produce a targeted protein. Investors typically watch such firms for clinical and regulatory milestones, but the article’s angle was explicitly technical.

The post did not provide, in the information available here, the names or tickers of the three other companies it flagged, nor did it detail what each of the five conditions specifically were. It also did not state whether those stocks showed similar catalysts around the time of the setup, or whether the match was based solely on trading charts and market behavior.

Sector context matters because investors sometimes interpret biotech rallies as a announcement to rotate into high-volatility growth. The article’s emphasis that none of the three matches were biotech suggests the rotation may be driven by market positioning and liquidity patterns rather than by a shared fundamental story across industries.

What to watch next is whether the three identified stocks continue to behave as their technical profiles imply, and whether follow-through depends on new information or fades as the market absorbs the initial momentum. The key uncertainty is that the screening criteria and the exact company list were not available in the metadata provided, so readers will need the full post content to evaluate the matchup precisely.